Pharmacologic treatments for covid-19 patients
Baricitinib+Remdesivir vs Remdesivir
This comparison will not be updated. Last search date 14 Dec, 2022.
Hospitalized patients
Forest plots
(last update: 2022-11-04)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=176
Back to your research
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| NCT04401579 ACTT-2 Kalil AC, N Engl J Med, 2020 Full text Full text Commentary |
Public/non profit |
Baricitinib+Remdesivir |
Placebo+Remdesivir |
RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 67 centers in Denmark, Japan, Mexico, Singapore, South Korea, Spain, UK, USA. | N=1033 |
Low Details |
|